Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy

Journal of Immunotherapy

Volumn 35, Issue 5, 2012, Pages 418-429

  Hornig, Nora ^a   Kermer, Vanessa ^a   Frey, Katharina ^a   Diebolder, Philipp ^a   Kontermann, Roland E ^a   Müller, Dafne ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

Author keywords

4 1BBL; B7.2; Bispecific antibody; Combinatorial immunotherapy; Costimulation

Indexed keywords

BISPECIFIC ANTIBODY; CD137 LIGAND; CD86 ANTIGEN; ENDOGLIN; FIBROBLAST ACTIVATION PROTEIN; GAMMA INTERFERON; HYBRID PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; GELATINASES; HEK293 CELLS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LIGANDS; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS; SERINE ENDOPEPTIDASES; T-LYMPHOCYTES, REGULATORY; TRANSFECTION;

EID: 84861232516     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3182594387     Document Type: Article

References (62)

1. Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev. 2009;229:126-144.
2. Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 2007;13(pt 1):5271-5279. (Pubitemid 47510350)
3. Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol. 2009;157:9-19.
4. Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7:95-106. (Pubitemid 46160986)
5. Coyle AJ, Gutierrez-Ramos JC. The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol. 2001;2:203-209. (Pubitemid 33705995)
6. Wang C, Lin GH, McPherson AJ, et al. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev. 2009;229:192-215.
7. deBenedette MA, Shahinian A, Mak T, et al. Costimulation of CD28-T lymphocytes by 4-1BB ligand. J. Immunol. 1997; 158:551-559. (Pubitemid 127492629)
8. Saoulli K, Lee SY, Cannons JL, et al. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J Exp Med. 1998;187:1849-1862. (Pubitemid 28262448)
9. Melero I, Bach N, Hellström KE, et al. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J Immunol. 1998;28:1116-1121. (Pubitemid 28116225)
10. Habib-Agahi M, Jaberipour M, Searle PF. 4-1BBL costimulation retrieves CD28 expression in activated T cells. Cell Immunol. 2009;256:39-46.
11. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 1993;259:368-370. (Pubitemid 23055679)
12. Bai XF, Bender J, Liu J, et al. Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens. J Immunol. 2001;167:3936-3943. (Pubitemid 32910839)
13. Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T cell activation molecule eradicate established tumors. Nat Med. 1997;3:682-685. (Pubitemid 27264981)
14. Miller RE, Jones J, Le T, et al. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol. 2002;169:1792-1800. (Pubitemid 34857639)
15. Martinet O, Divino CM, Zang Y, et al. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer. Gene Ther. 2002;9:786-792. (Pubitemid 34679306)
16. Guinn BA, DeBenedette MA, Watts TH, et al. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol. 1999;162:5003-5010. (Pubitemid 29314909)
17. Li G, Wu X, Zhang F, et al. Triple expression of B7-1, B7-2 and 4-1BBL enhanced antitumor immune response against mouse H22 hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;137:695-703.
18. Mü ller D, Kontermann RE. Bispecific antibodies for cancer immunotherapy: current perspectives. BioDrugs. 2010;24: 89-98.
19. Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev. 2010;36:458-467.
20. Baeuerle PA, Kufer P, Bargou R. BiTE: teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther. 2009;11:22-30.
21. Mueller D, Karle A, Meissburger B, et al. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem. 2007;282:12650-12660. (Pubitemid 47100581)
22. Mü ller D, Frey K, Kontermann RE. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy. J Immunother. 2008;31:714-722.
23. Bauer S, Renner C, Juwana JP, et al. Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo. Cancer Res. 1999;59:1961-1965. (Pubitemid 29186172)
24. Cochlovius B, Kipriyanov SM, Stassar MJ, et al. Treatment of human B cell lymphoma xenografts with a CD3-CD19 diabody and T cells. J Immunol. 2000;165:888-895. (Pubitemid 30484756)
25. Blanco B, Holliger P, Vile RG, et al. Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from genemodified bystander cells. J Immunol. 2003;171:1070-1077. (Pubitemid 36871424)
26. Guo H, Jiang W, Liu W, et al. Extracellular domain of 4-1BBL enhanced the antitumoral efficacy of peripheral blood lymphocytes mediated by anti-CD3-anti-Pgp bispecific diabody against human multidrug-resistant leukemia. Cell Immunol. 2008;251:102-108.
27. Liu R, Jiang W, Yang M, et al. Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies. J Immunother. 2010;33:500-509.
28. -/-knock-out mouse. Mol Med. 2001;7:461-469. (Pubitemid 33701967)
29. Vö lkel T, Mü ller R, Kontermann RE. Isolation of endothelial cell-specific human antibodies from a novel fully synthetic scFv library. Biochem Biophys Res Commun. 2004;317:515-521. (Pubitemid 38452512)
30. Cochran WG, Cox GM. Experimental Designs. 2nd ed. Oxford, UK: John Wiley & Sons; 1992.
31. Zhu Z, Carter P. Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation. J Immunol. 1995;155:1903-1910.
32. Niu L, Strahotin S, Hewes B, et al. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol. 2007;178:4194-4213. (Pubitemid 46492370)
33. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018-1028. (Pubitemid 44343545)
34. Thompson ED, Enriquez HL, Fu YX, et al. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med. 2010;207:1791-1804.
35. Rennert P, Furlong K, Jellis C, et al. The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion. Int Immunol. 1997;9:805-813. (Pubitemid 27231959)
36. Sturmhoefel K, Lee K, Gray GS, et al. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant. Cancer Res. 1999;59: 4964-4972. (Pubitemid 29472902)
37. Notter M, Willinger T, Erben U, et al. Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells. Blood. 2001;97:3138-3145.
38. Challita-Eid PM, Penichet ML, Shin SU, et al. A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway. J Immunol. 1998;160:3419-3426. (Pubitemid 28164735)
39. Gerstmayer B, Altenschmidt U, Hoffmann M, et al. Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 protooncogene. J Immunol. 1997;158:4584-4590. (Pubitemid 127483776)
40. Rabu C, Quéméner A, Jacques Y, et al. Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity. J Biol Chem. 2005;280:41472-41481. (Pubitemid 41832207)
41. Wyzgol A, Mü ller N, Fick A, et al. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J Immunol. 2009;183:1851-1861.
42. Schneider P, Holler N, Bodmer JL, et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med. 1998;187:1205-1213. (Pubitemid 28189110)
43. Mü ller N, Wyzgol A, Mü nkel S, et al. Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization. FEBS J. 2008;275:2296-2304. (Pubitemid 351569566)
44. Melero I, Martinez-Forero I, Dubrot J, et al. Palettes of vaccines and immunostimulatory monoclonal antibodies for combination. Clin Cancer Res. 2009;15:1507-1509.
45. Rajasekaran K, Xiong V, Fong L, et al. Functional dichotomy between NKG2D and CD28-mediated co-stimulation in human CD8+ T cells. PLoS One. 2010;5:pii. e12635.
46. Wen T, Bukczynski J, Watts TH. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol. 2002;168:4897-4906. (Pubitemid 34495951)
47. Kober J, Leitner J, Klauser C, et al. The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur J Immunol. 2008; 38:2678-2688.
48. Shuford WW, Klussman K, Tritchler DD, et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med. 1997;186:47-55. (Pubitemid 27304846)
49. Maus MV, Thomas AK, Leonard DG, et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol. 2002;20:143-148. (Pubitemid 34158029)
50. Rudolf D, Silberzahn T, Walter S, et al. Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells. Cancer Immunol Immunother. 2008;57:175-183. (Pubitemid 350159919)
51. Brischwein K, Schlereth B, Guller B, et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol. 2006;43:1129-1143. (Pubitemid 43063166)
52. Kischel R, Hausmann S, Klinger M, et al. Effector memory T cells make a major contribution to redirected target cell lysis by T cell-engaging BiTE antibody MT110. AACR Annual Meeting, poster #3252, 2009.
53. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-1964. (Pubitemid 44498003)
54. Pagè s F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27:5944-5951.
55. Koristka S, Cartellieri M, Theil A, et al. Retargeting of human regulatory T cells by single-chain bispecific antibodies. J Immunol. 2012;188:1551-1558.
56. Amann M, D'Argouges S, Lorenczewski G, et al. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J Immunother. 2009;32:452-464.
57. Elpek KG, Yolcu ES, Franke DD, et al. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J Immunol. 2007;179: 7295-7304.
58. So T, Lee SW, Croft M. Immune regulation and control of regulatory T cells by OX40 and 4-1BB. Cytokine Growth Factor Rev. 2008;19:253-262.
59. Bour-Jordan H, Bluestone JA. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev. 2009;229:41-66.
60. Laux I, Khoshnan A, Tindell C, et al. Response differences between human CD4(+) and CD8(+) T-cells during CD28 costimulation: implications for immune cell-based therapies and studies related to the expansion of double-positive T-cells during aging. Clin Immunol. 2000;96:187-197.
61. Zhang H, Snyder KM, Suhoski MM, et al. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol. 2007;179: 4910-4918.
62. Strome SE, Martin B, Flies D, et al. Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4-1BB costimulation of tumor-reactive T cells against a poorly immunogenic, major histocompatibility complex class I-negative A9P melanoma. J Immunother. 2000;23:430-437. (Pubitemid 30457700)